Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 2011

View Archived Issues

Study finds biomarkers of metastatic disease progression in prostate cancer

Therapy benefits children with Tay-Sachs and Sandhoff's diseases / News in Context

Phase II and III data presented on vorinostat

Xencor commences phase I study of immunotherapy for autoimmune diseases

AMG-827 improves quality of life in patients with plaque psoriasis

Phase III trial shows safety/tolerability of BG-12 in MS

FDA approves adjunctive therapy for Lennox-Gastaut syndrome

Adolor to be acquired by Cubist Pharmaceuticals

Mesoblast clear to begin phase II stem cell therapy trial for wet AMD

CHMP maintains earlier opinion after reexamining Glybera MAA

New phosphodiesterase 10A inhibitors prepared by Roche

Novartis provides update on regulatory timelines for NVA-237 and QVA-149

Novel B-raf inhibitors disclosed by Boehringer Ingelheim

Ajinomoto presents new factor Xa inhibitors

CHMP issues opinion on approval of Bronchitol

Vertex begins global phase IIIb Incivek combination study

Novel spider venom-derived contraceptive peptides designed in Chile

FDA to discuss Alexza Pharmaceuticals' NDA for Adasuve

Neuralstem receives FDA approval to advance ongoing ALS trial

Gilead and GlobeImmune enter HBV vaccine collaboration

Cell Therapeutics resubmits pixantrone NDA

Study establishes hENT1 cutoff level for LEAP trial

FDA advisory committee to review Affymax's peginesatide NDA

Karo Bio to spin off preclinical activities

MolMed expands phase III trial of NGR-hTNF

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...